OA10901A - Benzamide treatment of dementia associated with aids virus (hiv-1) infection - Google Patents

Benzamide treatment of dementia associated with aids virus (hiv-1) infection Download PDF

Info

Publication number: OA10901A
Authority: OA; OAPI
Prior art keywords: butyl; acetamidobenzamide; hiv; pharmaceutical composition; rerr
Prior art date: 1996-04-17

Application number

OA9800198A

Other languages

English (en)

Inventor

William Garland

Original Assignee

Centaur Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-17

Filing date

1998-10-16

Publication date

2002-02-14

1998-10-16 Application filed by Centaur Pharmaceuticals Inc filed Critical Centaur Pharmaceuticals Inc

2002-02-14 Publication of OA10901A publication Critical patent/OA10901A/en

Links

206010012289 Dementia Diseases 0.000 title claims abstract description 44
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title claims abstract description 38
238000011282 treatment Methods 0.000 title claims abstract description 27
241000700605 Viruses Species 0.000 title description 4
208000015181 infectious disease Diseases 0.000 title description 4
239000000203 mixture Substances 0.000 claims abstract description 15
230000000069 prophylactic effect Effects 0.000 claims abstract description 5
230000001225 therapeutic effect Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 46
238000000034 method Methods 0.000 claims description 38
239000008194 pharmaceutical composition Substances 0.000 claims description 16
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
-1 benzamide compound Chemical class 0.000 claims description 9
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
WFKPHYKFAOXUTI-UHFFFAOYSA-N NP-101A Chemical compound CC(=O)NC1=CC=CC=C1C(N)=O WFKPHYKFAOXUTI-UHFFFAOYSA-N 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 31
230000000694 effects Effects 0.000 abstract description 5
208000031886 HIV Infections Diseases 0.000 abstract description 4
208000037357 HIV infectious disease Diseases 0.000 abstract description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 4
230000009385 viral infection Effects 0.000 abstract description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 37
238000012360 testing method Methods 0.000 description 30
238000002474 experimental method Methods 0.000 description 26
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 21
210000004556 brain Anatomy 0.000 description 21
KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical class NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 20
102100040247 Tumor necrosis factor Human genes 0.000 description 18
230000009435 amidation Effects 0.000 description 18
238000007112 amidation reaction Methods 0.000 description 18
150000003936 benzamides Chemical class 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
229910052739 hydrogen Inorganic materials 0.000 description 11
229940054066 benzamide antipsychotics Drugs 0.000 description 10
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 9
208000030507 AIDS Diseases 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
210000002569 neuron Anatomy 0.000 description 8
241000700159 Rattus Species 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
229940125904 compound 1 Drugs 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
230000006907 apoptotic process Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
IYSYLWYGCWTJSG-XFXZXTDPSA-N n-tert-butyl-1-phenylmethanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1 IYSYLWYGCWTJSG-XFXZXTDPSA-N 0.000 description 6
210000003061 neural cell Anatomy 0.000 description 6
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000029251 gravitaxis Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
210000001130 astrocyte Anatomy 0.000 description 4
230000003542 behavioural effect Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000013467 fragmentation Methods 0.000 description 4
238000006062 fragmentation reaction Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000009102 absorption Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000004958 brain cell Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
ZPYLRHGQFFDNOH-UHFFFAOYSA-N n-butyl-4-nitrobenzamide Chemical compound CCCCNC(=O)C1=CC=C([N+]([O-])=O)C=C1 ZPYLRHGQFFDNOH-UHFFFAOYSA-N 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000003961 neuronal insult Effects 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000035899 viability Effects 0.000 description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
DNVFOBRRLYURPJ-UHFFFAOYSA-N 4-acetamido-n-butylbenzamide Chemical compound CCCCNC(=O)C1=CC=C(NC(C)=O)C=C1 DNVFOBRRLYURPJ-UHFFFAOYSA-N 0.000 description 2
ZMTHURUXFAZBJC-UHFFFAOYSA-N 4-acetamido-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=C(NC(C)=O)C=C1 ZMTHURUXFAZBJC-UHFFFAOYSA-N 0.000 description 2
AGOBSEMYQBQCAL-UHFFFAOYSA-N 4-acetamido-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=C(NC(C)=O)C=C1 AGOBSEMYQBQCAL-UHFFFAOYSA-N 0.000 description 2
BEPRYLWKWWVVQA-UHFFFAOYSA-N 4-nitro-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=C([N+]([O-])=O)C=C1 BEPRYLWKWWVVQA-UHFFFAOYSA-N 0.000 description 2
MDRVSZJDSUDYGP-UHFFFAOYSA-N 4-nitro-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=C([N+]([O-])=O)C=C1 MDRVSZJDSUDYGP-UHFFFAOYSA-N 0.000 description 2
206010065040 AIDS dementia complex Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150041968 CDC13 gene Proteins 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
229960003805 amantadine Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
210000000274 microglia Anatomy 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
YKWAXXNNKZSHDA-UHFFFAOYSA-N n-(2-methylbutyl)-4-nitrobenzamide Chemical compound CCC(C)CNC(=O)C1=CC=C([N+]([O-])=O)C=C1 YKWAXXNNKZSHDA-UHFFFAOYSA-N 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000002581 neurotoxin Substances 0.000 description 2
231100000618 neurotoxin Toxicity 0.000 description 2
210000004248 oligodendroglia Anatomy 0.000 description 2
DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000000047 product Substances 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
VPGHVKMBMPDAJD-UHFFFAOYSA-N 2,3-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1[N+]([O-])=O VPGHVKMBMPDAJD-UHFFFAOYSA-N 0.000 description 1
NKFYAZMEUHDEFV-UHFFFAOYSA-N 2,5-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C([N+]([O-])=O)C(C(Cl)=O)=C1 NKFYAZMEUHDEFV-UHFFFAOYSA-N 0.000 description 1
ZYDGHQSJZAFMLU-UHFFFAOYSA-N 2,6-dinitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1C#N ZYDGHQSJZAFMLU-UHFFFAOYSA-N 0.000 description 1
ROKOJFJDMZGGHK-UHFFFAOYSA-N 2,6-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1C(Cl)=O ROKOJFJDMZGGHK-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
YHVKCTDPZNSLCY-UHFFFAOYSA-N 2-acetamido-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=CC=C1NC(C)=O YHVKCTDPZNSLCY-UHFFFAOYSA-N 0.000 description 1
YREKETPBJSEWCJ-UHFFFAOYSA-N 2-amino-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=CC=C1N YREKETPBJSEWCJ-UHFFFAOYSA-N 0.000 description 1
VJROPLWGFCORRM-UHFFFAOYSA-N 2-methylbutan-1-amine Chemical compound CCC(C)CN VJROPLWGFCORRM-UHFFFAOYSA-N 0.000 description 1
SWBDKCMOLSUXRH-UHFFFAOYSA-N 2-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1C#N SWBDKCMOLSUXRH-UHFFFAOYSA-N 0.000 description 1
ZEMNPBSGWVIXTF-UHFFFAOYSA-N 3,4-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1[N+]([O-])=O ZEMNPBSGWVIXTF-UHFFFAOYSA-N 0.000 description 1
UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 1
NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
SHLKXOPGKOBICJ-UHFFFAOYSA-N 4-acetamido-n-(2-methylbutyl)benzamide Chemical compound CCC(C)CNC(=O)C1=CC=C(NC(C)=O)C=C1 SHLKXOPGKOBICJ-UHFFFAOYSA-N 0.000 description 1
ZPZOHCFZAZHHAQ-UHFFFAOYSA-N 4-acetamido-n-(2-methylpropyl)benzamide Chemical compound CC(C)CNC(=O)C1=CC=C(NC(C)=O)C=C1 ZPZOHCFZAZHHAQ-UHFFFAOYSA-N 0.000 description 1
HUHIIBPKBXASGB-UHFFFAOYSA-N 4-acetamido-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=C(NC(C)=O)C=C1 HUHIIBPKBXASGB-UHFFFAOYSA-N 0.000 description 1
YICAMJWHIUMFDI-UHFFFAOYSA-N 4-acetamidotoluene Chemical compound CC(=O)NC1=CC=C(C)C=C1 YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 description 1
OIHHACBSVFSFLI-UHFFFAOYSA-N 4-amino-n-(2-methylbutyl)benzamide Chemical compound CCC(C)CNC(=O)C1=CC=C(N)C=C1 OIHHACBSVFSFLI-UHFFFAOYSA-N 0.000 description 1
FLXMHAHQLCYFOI-UHFFFAOYSA-N 4-amino-n-butylbenzamide Chemical compound CCCCNC(=O)C1=CC=C(N)C=C1 FLXMHAHQLCYFOI-UHFFFAOYSA-N 0.000 description 1
XZGYRURAYYNRPY-UHFFFAOYSA-N 4-amino-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=C(N)C=C1 XZGYRURAYYNRPY-UHFFFAOYSA-N 0.000 description 1
MPSUFQMXTCIJCF-UHFFFAOYSA-N 4-amino-n-propylbenzamide Chemical compound CCCNC(=O)C1=CC=C(N)C=C1 MPSUFQMXTCIJCF-UHFFFAOYSA-N 0.000 description 1
YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
YQLNAYKZWIVHIN-UHFFFAOYSA-N 4-nitro-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQLNAYKZWIVHIN-UHFFFAOYSA-N 0.000 description 1
ZESWUEBPRPGMTP-UHFFFAOYSA-N 4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1 ZESWUEBPRPGMTP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
101100149246 Caenorhabditis elegans sem-4 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108010021119 Trichosanthin Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006741 behavioral dysfunction Effects 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical group 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 description 1
229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
IBVJFULICYLKCE-BDVNFPICSA-N methyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]carbamodithioic acid Chemical compound SC(=S)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IBVJFULICYLKCE-BDVNFPICSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
229960004938 molindone Drugs 0.000 description 1
230000007659 motor function Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
FCEWVSZNHBQUKC-UHFFFAOYSA-N n,n-dinitrobenzamide Chemical compound [O-][N+](=O)N([N+]([O-])=O)C(=O)C1=CC=CC=C1 FCEWVSZNHBQUKC-UHFFFAOYSA-N 0.000 description 1
UFKRTEWFEYWIHD-UHFFFAOYSA-N n-(4-cyanophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C#N)C=C1 UFKRTEWFEYWIHD-UHFFFAOYSA-N 0.000 description 1
NQWMXRNYYFMIIL-UHFFFAOYSA-N n-butan-2-yl-4-nitrobenzamide Chemical compound CCC(C)NC(=O)C1=CC=C([N+]([O-])=O)C=C1 NQWMXRNYYFMIIL-UHFFFAOYSA-N 0.000 description 1
CWRIIGJCKWITQT-UHFFFAOYSA-N n-tert-butyl-3-nitrobenzamide Chemical compound CC(C)(C)NC(=O)C1=CC=CC([N+]([O-])=O)=C1 CWRIIGJCKWITQT-UHFFFAOYSA-N 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940100684 pentylamine Drugs 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
KRFSWOJRIJXMMP-LJTMIZJLSA-N sodium;(2s,3r,4r,5r)-1-[bis(sulfanyl)methyl-methylamino]-3,4,5,6-tetrahydroxyhexan-2-olate Chemical compound [Na+].SC(S)N(C)C[C@H]([O-])[C@@H](O)[C@H](O)[C@H](O)CO KRFSWOJRIJXMMP-LJTMIZJLSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000009003 standardized kity Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
150000003613 toluenes Chemical class 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA9800198A 1996-04-17 1998-10-16 Benzamide treatment of dementia associated with aids virus (hiv-1) infection OA10901A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1571096P	1996-04-17	1996-04-17

Publications (1)

Publication Number	Publication Date
OA10901A true OA10901A (en)	2002-02-14

Family

ID=21773101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800198A OA10901A (en)	1996-04-17	1998-10-16	Benzamide treatment of dementia associated with aids virus (hiv-1) infection

Country Status (11)

Country	Link
EP (1)	EP0912171A1 (is)
CN (1)	CN1218399A (is)
AP (1)	AP898A (is)
AU (1)	AU720578B2 (is)
BR (1)	BR9708720A (is)
CA (1)	CA2252403A1 (is)
IS (1)	IS4868A (is)
NZ (1)	NZ332438A (is)
OA (1)	OA10901A (is)
TW (1)	TW412421B (is)
WO (1)	WO1997038684A1 (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ534884A (en)	2002-02-13	2007-05-31	Creagri Inc	Method and composition for treatment of inflammation and AIDS-associated neurological disorders
JP6750177B2 (ja) *	2015-12-11	2020-09-02	ロート製薬株式会社	アントラニルアミド誘導体およびそれを含有するｔｌｒ３が関与する疾患の治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5472983A (en) *	1994-04-14	1995-12-05	Centaur Pharmaceuticals, Inc.	Benzamide-containing pharmaceutical compositions
IL117629A (en) *	1995-04-03	2000-08-13	Centaur Pharmaceuticals Inc	Pharmaceutical compositions containing a benzamide derivative and methods for the preparation thereof

1997
- 1997-04-17 NZ NZ332438A patent/NZ332438A/en unknown
- 1997-04-17 WO PCT/US1997/006351 patent/WO1997038684A1/en not_active Ceased
- 1997-04-17 CA CA 2252403 patent/CA2252403A1/en not_active Abandoned
- 1997-04-17 BR BR9708720-3A patent/BR9708720A/pt not_active Application Discontinuation
- 1997-04-17 AP APAP/P/1998/001368A patent/AP898A/en active
- 1997-04-17 CN CN 97194582 patent/CN1218399A/zh active Pending
- 1997-04-17 AU AU27322/97A patent/AU720578B2/en not_active Ceased
- 1997-04-17 TW TW86104991A patent/TW412421B/zh active
- 1997-04-17 EP EP97921220A patent/EP0912171A1/en not_active Ceased
1998
- 1998-10-16 OA OA9800198A patent/OA10901A/en unknown
- 1998-10-16 IS IS4868A patent/IS4868A/is unknown

Also Published As

Publication number	Publication date
WO1997038684A1 (en)	1997-10-23
TW412421B (en)	2000-11-21
BR9708720A (pt)	2000-01-04
CN1218399A (zh)	1999-06-02
AP898A (en)	2000-11-17
AU720578B2 (en)	2000-06-08
CA2252403A1 (en)	1997-10-23
EP0912171A1 (en)	1999-05-06
AP9801368A0 (en)	1998-12-31
AU2732297A (en)	1997-11-07
IS4868A (is)	1998-10-16
NZ332438A (en)	2001-02-23

Publication	Publication Date	Title
Kieburtz et al.	1991	Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex: therapeutic implications
US5659082A (en)	1997-08-19	Nitro- and aminobenzamide compounds for neurodegenerative disorders
US6509378B2 (en)	2003-01-21	Acetamidobenzamide compounds for neurodegenerative disorders
EP0755250A1 (en)	1997-01-29	Benzamide-containing pharmaceutical compositions
JP3479658B2 (ja)	2003-12-15	神経変性障害処置のためのベンズアミド
AU720578B2 (en)	2000-06-08	Benzamide treatment of dementia associated with AIDS virus (HIV-1) infection
US6077870A (en)	2000-06-20	Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders
MXPA98008661A (en)	1999-04-27	Benzamide treatment of associated dementia the infection for the virus of the acquired immunodeficiency syndrome (human immunodeficiency virus)
US6140369A (en)	2000-10-31	Benzamides for neurodegenerative disorder treatment
US5914350A (en)	1999-06-22	Pharmaceutical compositions of nitro- and aminobenzamide compounds for neurodegenerative disorders
AU725432B2 (en)	2000-10-12	Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection
HK1020869A (en)	2000-05-26	Benzamide treatment of demential associated with aids virus (hiv-1) infection